Every DEF 14A that Envoy Medical (COCH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow COCH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COCH filings page.
Envoy Medical, Inc. (COCH) is asking stockholders at an October 12, 2026 special meeting to approve an amendment authorizing the Board, at its discretion, to implement one or more reverse stock splits of the Class A common stock within a 1‑for‑5 to 1‑for‑25 range any time through December 31, 2026. As of August 19, 2026, there were 77,394,595 Class A shares outstanding and entitled to vote.
The stated primary goal is to regain compliance with Nasdaq’s $1.00 minimum bid price requirement after Envoy received deficiency notices and a final compliance deadline of November 16, 2026. The split would not change authorized share counts or par value, and fractional shares would be cashed out. Envoy warns that the split may not sustain a higher price, could reduce liquidity, and failure to lift and maintain the price above $1.00 could lead to Nasdaq delisting, limiting access to capital. A second proposal would allow adjournment of the meeting to solicit additional proxies if needed.
Envoy Medical is asking stockholders to approve several items at its May 12, 2026 annual meeting, including electing two Class III directors and ratifying EisnerAmper LLP as new auditor after dismissing Grant Thornton, whose prior reports included substantial doubt about the company’s ability to continue as a going concern and cited material weaknesses in internal control.
Stockholders will vote on an advisory say-on-pay proposal, a major amendment to the 2023 Equity Incentive Plan adding 6,000,000 shares for a total of 10,000,000, and an amendment to the Employee Stock Purchase Plan increasing its reserve by 1,200,000 to 1,500,000 shares. They are also asked to approve, under Nasdaq Listing Rule 5635(d), the exercisability of warrants issued in a February 12, 2026 financing, covering up to 123,750,000 shares of Class A common stock, which could significantly increase the company’s share count if fully exercised.
Envoy Medical called a special stockholders’ meeting on November 26, 2025 to approve, under Nasdaq Listing Rule 5635(d), the exercisability of newly issued warrants and the issuance of the Class A Common Stock underlying them. The warrants stem from a September 2025 financing: Private Warrants to purchase up to 5,725,206 shares at $1.31 and Placement Agent Warrants for 143,130 shares at $1.6375, plus additional placement agent warrants equal to 7.5% of Private Warrant exercises. These warrants become exercisable only after stockholder approval.
If all Private and Placement Agent Warrants are exercised, an additional 6,297,726 shares would be outstanding. The company states it would realize up to approximately $8.4 million in gross proceeds upon full exercise. Shares outstanding were 23,809,975 as of October 2, 2025. The Board unanimously recommends voting FOR both the Issuance Proposal and a potential meeting adjournment to solicit additional proxies. A voting agreement indicates the Taylor Parties, who beneficially own approximately 43.2%, will vote in favor of the issuance.